Exclusive: Could Zimmer Biomet Holdings Inc Lose Strenght? The Stock Increases A Lot Today

Exclusive: Could Zimmer Biomet Holdings Inc Lose Strenght? The Stock Increases A Lot Today

The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) is a huge mover today! About 605,556 shares traded hands. Zimmer Biomet Holdings Inc (NYSE:ZBH) has declined 11.48% since April 26, 2016 and is downtrending. It has underperformed by 16.74% the S&P500.
The move comes after 6 months positive chart setup for the $20.66 billion company. It was reported on Nov, 29 by Barchart.com. We have $109.72 PT which if reached, will make NYSE:ZBH worth $1.24 billion more.

Analysts await Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings on January, 26. They expect $2.11 EPS, up 0.96% or $0.02 from last year’s $2.09 per share. ZBH’s profit will be $421.14M for 12.26 P/E if the $2.11 EPS becomes a reality. After $1.79 actual EPS reported by Zimmer Biomet Holdings Inc for the previous quarter, Wall Street now forecasts 17.88% EPS growth.

Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage

Out of 16 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 12 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 75% are positive. Zimmer Biomet Holdings has been the topic of 24 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Nomura initiated the shares of ZBH in a report on Thursday, March 17 with “Buy” rating. The stock has “Sell” rating given by Citigroup on Thursday, November 12. The firm has “Strong Buy” rating by Needham given on Tuesday, November 1. Northcoast downgraded Zimmer Biomet Holdings Inc (NYSE:ZBH) on Tuesday, November 8 to “Neutral” rating. The company was maintained on Tuesday, August 23 by Barclays Capital. The company was downgraded on Friday, August 28 by Zacks. The stock has “Buy” rating given by Canaccord Genuity on Friday, September 4. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) has “Neutral” rating given on Thursday, June 9 by Guggenheim. The company was initiated on Tuesday, September 22 by UBS. The firm has “Overweight” rating by Barclays Capital given on Friday, April 29.

According to Zacks Investment Research, “Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States.”

More notable recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: Wsj.com which released: “Zimmer Biomet Cuts Forecasts” on October 31, 2016, also Forbes.com with their article: “Zimmer Biomet Holdings Becomes Oversold (ZBH)” published on November 22, 2016, Reuters.com published: “BRIEF-Seikagaku signs exclusive distribution agreement with Zimmer Biomet …” on November 08, 2016. More interesting news about Zimmer Biomet Holdings Inc (NYSE:ZBH) were released by: Prnewswire.com and their article: “ZIMMER BIOMET (ZBH) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP …” published on November 02, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: November 01, 2016.

ZBH Company Profile

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., incorporated on January 12, 2001, is engaged in designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma (S.E.T.) products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. The Firm manages its activities through three geographic operating divisions: the Americas, comprising principally of the United States and includes other North, Central and South American markets; EMEA, comprising of principally of Europe and includes the Middle East and African markets, and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company’s four product category divisions include Americas Spine, Bone Healing Craniomaxillofacial and Thoracic (CMF) and Dental.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment